ScreenerHero

ONC BeOne Medicines AG

NAS · US · Healthcare · Biotechnology · beonemedicines.com
361.65USD+1.00%Mkt Cap: 41.14B $P/E: 64.70

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products incl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD
TWST
Twist Bioscience Corporation
$13.59BUSD

Key Statistics

Company
Market Cap41.14B USD
Enterprise Value37.66B USD
Revenue (TTM)6.13B USD
Gross Profit4.67B USD
Net Income (TTM)286.93M USD
Revenue/Share55.27 USD
Last Price361.65 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees12.0K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)64.70
P/E (Forward)34.94
PEG0.76
EV/EBITDA35.15
EV/Revenue6.15
P/S6.65
P/B7.82
EPS (TTM)5.59
EPS (Forward)10.25
52W Range
253.9582% of range385.22
52W High385.22 USD
52W Low253.95 USD
Profitability
Gross Margin87.49%
Oper. Margin19.06%
EBITDA Margin17.48%
Profit Margin5.37%
ROE6.58%
ROA3.50%
Growth
Revenue Growth29.60%
Earnings Growth166.70%
Cash Flow & Leverage
Operating CF1.13B USD
CapEx (TTM)266.53M USD
FCF Margin14.34%
FCF Yield2.14%
Net Debt-3.05B USD
Net Debt/EBITDA-2.84
Balance Sheet
Debt/Equity0.25
Current Ratio3.40
Quick Ratio2.91
Book Value/Sh45.78 USD
Cash/Share44.84 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)433.52 USD
Upside (mean)+19.9%
Target Range370.00 USD – 528.00 USD
370.00+19.9% to mean528.00
# Analysts28
Ownership
Shares Out.104.92M
Float80.96M
Insiders17.28%
Institutions33.17%
Short Interest
Short Ratio4.7d
Short % Float2.11%
Short % Out.1.50%
Shares Short1.71M
Short (prev mo.)1.28M
Technical
SMA 50353.31 (+2.4%)
SMA 200320.10 (+13.0%)
Beta0.52
S&P 52W Chg14.58%
Avg Vol (30d)371.71K
Avg Vol (10d)414.21K
Technical Indicators
RSI (14)54.0
MACD3.5112
MACD Signal4.2569
MACD Hist.-0.7457
BB Upper372.95 USD
BB Middle357.76 USD
BB Lower342.58 USD
BB Width8.49%
ATR (14)9.694 USD
Vol Ratio (20d)0.53x